As more cannabis companies go public and private businesses raise capital at an unprecedented clip, valuations have become a hot topic among industry observers, insiders and investors.
That’s especially true in Canada, where a growing number of cannabis firms have fetched multibillion-dollar valuations in the public markets as they’ve hustled to become a top player in the nation’s impending adult-use market.
“With cannabis in Canada, it’s a horse race right now,” said Patrick Rea, co-founder and CEO of Canopy Boulder, a Colorado-based cannabis-focused business accelerator. “Investors are asking ‘Who’s in front? I’m going to put money on that guy.’”
After its trading debut on the Nasdaq last week, British Columbia-based Tilray has a market cap in excess of $3 billion – more than 140 times its reported 2017 revenue of $20.5 million.
- Canopy Growth, which is traded on the Toronto Stock Exchange as WEED, has a market cap of roughly 7 billion Canadian dollars ($5.3 billion), with fiscal year 2018 revenue of CA$77.9 million.
- Aurora Cannabis (TSE: ACB) has a market cap of CA$4 billion, with 2017 revenue of CA$31.1 million.
- Aphria (TSE: APH) has a market cap of CA$2.4 billion, with 2017 revenue of CA$20.4 million.
Across the board, the market caps ring in at multiples of nearly 90 to more than 120 times each of the firms’ reported revenues.
“It is not unusual for an early stage, hypergrowth industry to receive high valuations,” said Scott Greiper, president at Viridian Capital Advisors.
Looking back at tech and other emerging industries, Greiper said it’s common for early stage markets to be valued on an “enterprise value to revenue multiple” – a metric used for high-growth businesses that don’t have a long history of positive earnings.
“This stage of market growth is all about market share, early revenue traction and an overall land grab,” he said.
But even given those considerations: “In the Canadian marketplace, valuations certainly seem excessive.”
How long those sky-high valuations might stick around remains to be seen, said Alan Brochstein, founder of 420 Investor, a Houston-based firm that advises interested cannabis investors.
“If you just look at the Canadian market, you’re going to struggle to justify the valuations that you’re seeing right now,” Brochstein said. “Without being critical, that’s a warning signal to investors.
“But valuations are hard in new industries for a number of reasons – and nobody knows the future.”
Betting on a future beyond Canada
By 2022, sales of legal cannabis in Canada are projected to grow to nearly $6 billion.
Even at that level, the Canadian market will be eclipsed by what could become an $18 billion-$22 billion industry in the United States, according to projections from the Marijuana Business Factbook 2018.
In part, it’s the market potential beyond Canada’s borders that’s luring investors to bet big on Canadian cannabis. They’re considering the advantages these firms have to be among the biggest and first to scale globally.
“The Canadian market – where the adult-use market will only be as big as California – does not have enough market potential to support the valuations currently given,” said Nick Kovacevich, CEO of California-based cannabis packing company Kush Bottles.
“Because of this, we are now seeing a rise in the number of Canadian companies aggressively moving internationally, a key advantage they have over U.S. companies.
“These international moves help open the market potential and allow those Canadian firms to justify their valuations.”
While it may be easier for Canadian firms to go global, Brochstein cautioned that much of that work lies ahead.
“The reality is, scaling up globally takes a lot of capital and a lot of partnerships,” he said. “It’s not an endeavor that is easily accomplished.”
Still, such growth potential could keep the generous valuations coming, industry insiders say.
In the U.S., Canadian cannabis companies buying up takeout targets and spinning off assets into new companies are poised to grow their market share as more states legalize, said Derek Peterson, CEO of Terra Tech, a vertically integrated MJ business with operations in California and Nevada.
“The influx of institutional capital into the space is resulting in consolidation in multiple marketplaces, and because of the limited amount of permits that exist, holders of those permits are experiencing a significant rise in their value,” he said.
The rising values “don’t necessarily mean that there is a bubble,” Kovacevich said. “For a bubble to occur it would mean that the valuations are getting higher than the market potential.
“With the ultimate U.S. market potential so big and new states coming online, I think there is room for loftier valuations.”
While the Canadian valuations “seem excessive,” Viridian’s Greiper said investment rationale in the space generally continues to be supported by strong fundamentals, including:
- The acceleration of cannabis industry sales and the pace of marijuana legalization on a global scale.
- The growing number of public cannabis companies in the U.S. and Canada that have been embraced by the capital markets – providing increased liquidity for marijuana stocks and investors.
- The gradual acceptance by major exchanges in the U.S., including the Nasdaq and New York Stock Exchange, in listing cannabis companies.
- Advanced technology being adopted by cannabis companies driving economies of scale, lower production costs and more efficient operations.
Harder to predict: Just when the market will begin to “shake out,” Greiper said.
When that finally begins to happen, investors will then begin valuing companies based on more typical metrics, such as EBITDA, operating income and cash flow.
For now, however, the race is on to be an early market leader.
“We’re at a moment in time where the interest is incredibly high – and investors are buying into that future potential based on who appears to be winning today,” Canopy Boulder’s Rea said.
Lisa Bernard-Kuhn can be reached at [email protected]